Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classifica tra le azioni #170
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Prezzo delle azioni
$519.38
Ultima sincronizzazione: 2026-09-14
Capitalizzazione di mercato
$131.82B
Variazione (1 giorno)
0.76%
Variazione (1 anno)
32.09%
Paese
US
Scambia Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Margine operativo per Vertex Pharmaceuticals Incorporated (VRTX)
Margine operativo al September 2026 TTM: 38.59%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Vertex Pharmaceuticals Incorporated, il margine operativo attuale (TTM) è 38.59%. Alla fine del 2023, il margine operativo era 38.83%.
Storico del margine operativo per Vertex Pharmaceuticals Incorporated da 2000 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
2026 (TTM) 38.59% -1,928.91%
2024 -2.11% -105.43%
2023 38.83% -19.49%
2022 48.23% 31.31%
2021 36.73% -20.20%
2020 46.03% 59.99%
2019 28.77% 38.05%
2018 20.84% 321.01%
2017 4.95% 753.45%
2016 0.58% -101.28%
2015 -45.40% -61.94%
2014 -119.30% 60.05%
2013 -74.54% -49,793.33%
2012 0.15% -98.14%
2011 8.07% -101.66%
2010 -485.51% -19.23%
2009 -601.10% 127.99%
2008 -263.65% 24.99%
2007 -210.94% 99.26%
2006 -105.86% 13.64%
2005 -93.15% -38.19%
2004 -150.71% -60.61%
2003 -382.59% 415.27%
2002 -74.25% 35.47%
2001 -54.81% 10.70%
2000 -49.51% 0.00%
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
28.81% -99.25%
NL
25.57% -99.34%
AU
-149.01% -103.86%
US
0.00% -
CH
31.23% -99.19%
BE
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.